Mark A Lewis1, Geoffrey B Thompson, William F Young. 1. Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. lewis.mark2@mayo.edu
Abstract
BACKGROUND: Many serologic and radiographic modalities are used for monitoring multiple endocrine neoplasia type 1 (MEN 1) patients for pancreaticoduodenal neuroendocrine tumors (PNETs). We compared serum markers and imaging studies obtained preoperatively with the gross pathology and immunohistochemical findings and correlated preoperative testing with postoperative outcome. METHODS: From 2000 to 2008, 52 MEN 1 patients [32 (62%) female; median age = 43 years, range 19-74 years] underwent 56 pancreatic operations [49 (88%) distal pancreatectomies] for suspected PNETs. Preoperative serum markers [human pancreatic polypeptide (HPP), gastrin, and glucagon] and imaging [CT, (111)In pentetreotide scintigraphy, and endoscopic ultrasound (EUS)] were compared to the pathologic findings. Postoperative serum markers and survival were followed. RESULTS: Human pancreatic polypeptide had the highest agreement between an elevated serum level and positive tumor immunostaining (83% vs. 50% agreement for gastrin vs. 67% agreement for glucagon). Preoperative CT had 81% sensitivity and positive predictive value (PPV) of 97% for PNETs. (111)In pentetreotide scintigraphy had 84% sensitivity and PPV of 96%. Preoperative endoscopic ultrasonography (EUS) had 100% sensitivity and PPV, with close correlation (r (s) = 0.93) between the largest lesion seen on EUS and pathology. Median follow-up was 4.3 years (range = 0.1-10.9 years). Overall survival was 89% at 5-year follow-up. CONCLUSIONS: Our study substantiates EUS as providing the highest preoperative sensitivity and PPV in assessing the presence of PNETs in MEN 1 patients. CT and octreotide scintigraphy can yield both false-positive and false-negative results. HPP, gastrin, and glucagon were the most commonly measured tumor markers in our series but did not always correlate with immunostaining. With an aggressive surgical approach, satisfactory rates of biochemical improvement and long-term survival were observed.
BACKGROUND: Many serologic and radiographic modalities are used for monitoring multiple endocrine neoplasia type 1 (MEN 1) patients for pancreaticoduodenal neuroendocrine tumors (PNETs). We compared serum markers and imaging studies obtained preoperatively with the gross pathology and immunohistochemical findings and correlated preoperative testing with postoperative outcome. METHODS: From 2000 to 2008, 52 MEN 1patients [32 (62%) female; median age = 43 years, range 19-74 years] underwent 56 pancreatic operations [49 (88%) distal pancreatectomies] for suspected PNETs. Preoperative serum markers [humanpancreatic polypeptide (HPP), gastrin, and glucagon] and imaging [CT, (111)In pentetreotide scintigraphy, and endoscopic ultrasound (EUS)] were compared to the pathologic findings. Postoperative serum markers and survival were followed. RESULTS:Humanpancreatic polypeptide had the highest agreement between an elevated serum level and positive tumor immunostaining (83% vs. 50% agreement for gastrin vs. 67% agreement for glucagon). Preoperative CT had 81% sensitivity and positive predictive value (PPV) of 97% for PNETs. (111)In pentetreotide scintigraphy had 84% sensitivity and PPV of 96%. Preoperative endoscopic ultrasonography (EUS) had 100% sensitivity and PPV, with close correlation (r (s) = 0.93) between the largest lesion seen on EUS and pathology. Median follow-up was 4.3 years (range = 0.1-10.9 years). Overall survival was 89% at 5-year follow-up. CONCLUSIONS: Our study substantiates EUS as providing the highest preoperative sensitivity and PPV in assessing the presence of PNETs in MEN 1patients. CT and octreotide scintigraphy can yield both false-positive and false-negative results. HPP, gastrin, and glucagon were the most commonly measured tumor markers in our series but did not always correlate with immunostaining. With an aggressive surgical approach, satisfactory rates of biochemical improvement and long-term survival were observed.
Authors: Detlef K Bartsch; Volker Fendrich; Peter Langer; Ilhan Celik; Peter H Kann; Matthias Rothmund Journal: Ann Surg Date: 2005-12 Impact factor: 12.969
Authors: M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: Jens Waldmann; Volker Fendrich; Nils Habbe; Detlef K Bartsch; Emily P Slater; Peter H Kann; Matthias Rothmund; Peter Langer Journal: World J Surg Date: 2009-06 Impact factor: 3.352
Authors: Katra Senica; Ales Tomazic; Ales Skvarca; Petra Kolenc Peitl; Renata Mikolajczak; Alicja Hubalewska-Dydejczyk; Luka Lezaic Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen Journal: Neuroendocrinology Date: 2016-01-05 Impact factor: 4.914
Authors: Dirk-Jan van Beek; Helena M Verkooijen; Sjoerd Nell; Bert A Bonsing; Casper H van Eijck; Harry van Goor; Frederik J H Hoogwater; Elisabeth J M Nieveen van Dijkum; Geert Kazemier; Cornelis H C Dejong; Lodewijk A A Brosens; Frank J Wessels; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens Journal: Neuroendocrinology Date: 2020-07-28 Impact factor: 4.914
Authors: Francesco Ferrara; Carmelo Luigiano; Antonella Maimone; Marco Bassi; Anna Maria Polifemo; Paola Baccarini; Vincenzo Cennamo; Nadia Cremonini; Carlo Fabbri Journal: Case Rep Oncol Med Date: 2012-10-10
Authors: Virendra A Patil; Manjunath R Goroshi; Hina Shah; Gaurav Malhotra; Priya Hira; Vijaya Sarathi; Vikram R Lele; Swati Jadhav; Anurag Lila; Tushar R Bandgar; Nalini S Shah Journal: World J Nucl Med Date: 2020-01-29